About 10x Genomics, Inc.
https://www.10xgenomics.com10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
CEO
Serge Saxonov
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2006-07-17 | Reverse | 1:2 |
ETFs Holding This Stock
Summary
Showing Top 3 of 157
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Canaccord Genuity
Buy
Stifel
Buy
Barclays
Overweight
Stephens & Co.
Overweight
Morgan Stanley
Equal Weight
Leerink Partners
Market Perform
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:13.27M
Value:$277.7M
ARK INVESTMENT MANAGEMENT LLC
Shares:11.89M
Value:$248.68M
BLACKROCK, INC.
Shares:9.46M
Value:$197.91M
Summary
Showing Top 3 of 382
About 10x Genomics, Inc.
https://www.10xgenomics.com10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $149M ▼ | $132.55M ▲ | $-27.47M ▼ | -18.44% ▼ | $-0.22 ▼ | $-15.95M ▼ |
| Q2-2025 | $172.91M ▲ | $94.96M ▼ | $34.54M ▲ | 19.97% ▲ | $0.28 ▲ | $46.65M ▲ |
| Q1-2025 | $154.88M ▼ | $144.77M ▼ | $-34.36M ▲ | -22.18% ▲ | $-0.28 ▲ | $-23.69M ▲ |
| Q4-2024 | $165.02M ▲ | $160.79M ▲ | $-49.03M ▼ | -29.71% ▼ | $-0.4 ▼ | $-37.82M ▼ |
| Q3-2024 | $151.65M | $147.88M | $-35.75M | -23.58% | $-0.3 | $-23.69M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $482.08M ▲ | $1.03B ▲ | $241.03M ▲ | $785.12M ▲ |
| Q2-2025 | $447.26M ▲ | $979.97M ▲ | $206.69M ▲ | $773.28M ▲ |
| Q1-2025 | $426.9M ▲ | $903.39M ▼ | $196.5M ▼ | $706.89M ▼ |
| Q4-2024 | $393.4M ▼ | $918.64M ▼ | $208.5M ▼ | $710.13M ▼ |
| Q3-2024 | $398.16M | $937.79M | $214.99M | $722.8M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-27.47M ▼ | $43.21M ▲ | $-8.8M ▼ | $617K ▼ | $35M ▲ | $42.53M ▲ |
| Q2-2025 | $34.54M ▲ | $17.71M ▼ | $-939K ▲ | $3.52M ▲ | $20.65M ▼ | $16.13M ▼ |
| Q1-2025 | $-34.36M ▲ | $34.35M ▲ | $-1.89M ▲ | $422K ▼ | $32.99M ▲ | $32.46M ▲ |
| Q4-2024 | $-49.03M ▼ | $-6.75M ▼ | $-51.59M ▼ | $4.52M ▲ | $-54.09M ▼ | $-9.46M ▼ |
| Q3-2024 | $-35.75M | $21.64M | $-3.62M | $156K | $18.34M | $17.75M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Consumables | $260.00M ▲ | $130.00M ▼ | $120.00M ▼ | $120.00M ▲ |
 Instruments | $50.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Licensing And Royalty Revenue | $0 ▲ | $0 ▲ | $20.00M ▲ | $30.00M ▲ |
 Product And Service Revenue | $0 ▲ | $150.00M ▲ | $140.00M ▼ | $150.00M ▲ |
 Service | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q3-2025 | Q2-2025 |
|---|---|---|---|---|
 Americas | $90.00M ▲ | $90.00M ▲ | $80.00M ▼ | $110.00M ▲ |
 AsiaPacific Excluding China | $10.00M ▲ | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ |
 CHINA | $10.00M ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
 EMEA | $50.00M ▲ | $30.00M ▼ | $40.00M ▲ | $30.00M ▼ |
 UNITED STATES | $0 ▲ | $0 ▲ | $80.00M ▲ | $0 ▼ |
CEO
Serge Saxonov
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2006-07-17 | Reverse | 1:2 |
ETFs Holding This Stock
Summary
Showing Top 3 of 157
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Canaccord Genuity
Buy
Stifel
Buy
Barclays
Overweight
Stephens & Co.
Overweight
Morgan Stanley
Equal Weight
Leerink Partners
Market Perform
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:13.27M
Value:$277.7M
ARK INVESTMENT MANAGEMENT LLC
Shares:11.89M
Value:$248.68M
BLACKROCK, INC.
Shares:9.46M
Value:$197.91M
Summary
Showing Top 3 of 382